Is Compounded Tirzepatide Safe?

Tirzepatide's legal status has changed a lot since 2024, which affects how safe it is to use. The FDA declared the tirzepatide shortage resolved, and that directly affects whether compounded versions can still legally be made and sold.

Compounded tirzepatide is not inherently unsafe, but it lacks FDA oversight, so safety depends entirely on the compounding pharmacy's quality controls. Risks include dosing errors, inconsistent potency, and contamination. FDA-approved Zepbound or Mounjaro remain the safer choice whenever accessible and affordable.

What is compounded tirzepatide?

Tirzepatide is the active ingredient in the two FDA-approved medications for weight loss, sleep apnea and type 2 diabetes, Zepbound and Mounjaro. Compounded tirzepatide is a version of the same active ingredient prepared by a compounding pharmacy. These compounding pharmacies mix, alter, or combine the active ingredient tirzepatide with other compounds, like vitamin B12 and glycine. 

In the case of tirzepatide specifically, compounded versions were typically made in bulk, often at much lower cost than the brand-name products. During the national shortages of GLP-1 medications, including Zepbound and Mounjaro, the FDA allowed compounding pharmacies to produce tirzepatide under specific exemptions. 

It is important to understand that compounded tirzepatide is not FDA-approved and hasn’t gone through the same review for safety, efficacy, and manufacturing quality standards that brand-name Zepbound and Mounjaro have, which is important to consider when weighing the risks.

Compounded tirzepatide vs Zepbound and Mounjaro

Here's how compounded tirzepatide differs from the FDA-approved brand-name versions, based on FDA guidance:

What is the FDA's current stance on compounded tirzepatide?

The FDA declared the tirzepatide shortage resolved on December 19, 2024. This had significant consequences for compounding pharmacies.

Under the current FDA regulations, compounding pharmacies are only legally allowed to essentially produce a copy of an FDA-approved medicine like tirzepatide when it is on the official shortage list. Once tirzepatide was removed from the shortage list, the legal basis for the majority of compounded tirzepatide went away. 

The FDA gave compounding pharmacies a transition period: 503A state-licensed pharmacies were given until February 18, 2025, and 503B outsourcing facilities had until March 19, 2025, to wind down compounding of tirzepatide. The courts denied multiple legal challenges argued by the compounding industry, and as of mid-2025, compounding a copy of tirzepatide isn’t legally permissible for 503A or 503B entities. 

To date, as of mid-2026, the FDA is taking further steps and has proposed a rule that would formally prevent 503B outsourcing facilities from bulk compounding of tirzepatide, which would remove both the bulk-list and shortage-list pathways for compounders permanently. 

What are the safety concerns with compounded tirzepatide?

Even when compounded tirzepatide was legally produced during the shortage, it still carried risks that brand-name products don't. Those risks are still relevant for anyone who has obtained or is considering using it.

Dosing errors

Zepbound comes in single-dose or multi-dose pens, as well as single-dose vials, which have exact pre-measured doses. Compounded tirzepatide generally comes in multi-dose vials, which require patients to draw their own dose. This doesn't guarantee an error but leaves real room for one. The FDA had received over 320 adverse event reports tied to compounded tirzepatide by early 2025. Many of these involved self-dosing errors, with some unfortunately requiring hospitalization. By May 2026, that number had grown to over 730.

A separate 2025 pharmacovigilance study comparing FDA adverse event reports found that compounded GLP-1 products, including tirzepatide, were linked to nearly 49 times higher odds of preparation errors and 19 times higher odds of contamination when compared to FDA-approved versions, along with higher rates of side effects like abdominal pain, diarrhea, and other complications.

Variable concentration and potency

Concentrations vary by pharmacy, so by using multiple pharmacies, or even getting a different batch from the same pharmacy, one can unintentionally give oneself a different dose. This isn't theoretical either, as a 2026 study testing impurities in tirzepatide/B12 products found that some samples contained as little as 43% of their labeled potency.

Unlisted additives and unknown interactions

Compounded tirzepatide is frequently sold combined with additives like vitamin B12 and glycine. The same study found that B12 can chemically bind to tirzepatide, creating a new molecular byproduct not found in FDA-approved products, with evidence showing this alters the drug's structure at levels up to 10% of total protein content. The clinical impact of this is still unknown. It's also worth noting that the study was funded by Eli Lilly, maker of Zepbound and Mounjaro.

This isn't a one-off. A separate 2026 study found dozens of 'unique' versions of compounded tirzepatide and semaglutide, like sublingual drops and dissolving tablets, sold to get around legal restrictions. The authors of the study found these products haven’t been tested, so it’s unclear how safe or effective they are.

Counterfeit and unregulated products

The FDA has flagged counterfeit tirzepatide sold online, sometimes containing the wrong ingredient, wrong dose, or harmful contaminants. Buying tirzepatide from an unverified online source always carries a potential risk of harm.

No premarket quality review

Since Zepbound and Mounjaro are made in FDA-inspected facilities under cGMP standards, factors like ingredient verification, sterility, dosing accuracy, and post-market monitoring are all ensured. Compounded versions, especially those created under 503A, aren't held to the same strict standards, meaning there's less assurance that the product is correctly dosed, sterile, or free of contaminants.

Compounded products made up 45% of all US drug recalls between 2012 and 2021, even though they're less than 3% of prescriptions, mostly because they weren't properly sterilized. The same 2026 study on tirzepatide/B12 impurities cited earlier also found that, specific to GLP-1 drugs, over 70,000 vials of compounded versions have been recalled since 2023 for the same reason.

Lack of long-term safety data

Tirzepatide's safety and efficacy data, including SURMOUNT-1 and SURMOUNT-4, came from Eli Lilly's pharmaceutical-grade product. No equivalent long-term data exists for compounded versions, which may differ in active ingredients, concentrations, preservatives, or stability.

The other thing to consider is that if you have any unexpected side effects while using compounded tirzepatide, it can be more challenging to pinpoint whether they’re caused by tirzepatide itself or the specific product formulation. If you experience any concerning side effects, be sure to speak with your healthcare provider.

What should you do if you're currently taking compounded tirzepatide?

If you've been prescribed compounded tirzepatide and are currently taking it, the most important step is to talk to your healthcare provider as soon as possible. Given the change in legal status, many providers will be transitioning patients to FDA-approved Zepbound or Mounjaro.

Here's what to discuss with your provider:

• Whether your current dose translates to a Zepbound or Mounjaro dose, since concentrations may differ

• Whether you're eligible for Zepbound or Mounjaro based on your diagnosis and insurance coverage

• Cost options, since savings programs are available for Zepbound and Mounjaro, that may reduce out-of-pocket costs

• Whether you have any contraindications to the brand-name formulations

Do not suddenly stop taking tirzepatide without speaking to your provider first. Stopping GLP-1 medications suddenly can lead to weight regain, and your provider may want to manage the transition carefully.

If you’re experiencing side effects that feel unusual or more severe than expected, especially nausea, vomiting, or severe abdominal pain, contact your provider. If you think you may have taken an incorrect dose, seek medical advice right away.

Red flags to watch for

Whether you're currently taking compounded tirzepatide or have been offered it from an online source, these are warning signs worth taking seriously:

• No valid prescription is required to purchase

• Product sold by an online pharmacy without a verifiable US address or pharmacist contact

• No concentration or lot number listed on the vial

• The product is significantly cheaper than anything available through licensed US pharmacies

• Packaging that looks inconsistent, unprofessional, or different from what you've received before

If any of these apply, do not use the product. Contact your healthcare provider and, if needed, report the product to the FDA through MedWatch.

The bottom line

The short answer is that compounded tirzepatide isn't necessarily unsafe, but there's no true guarantee either, and there's ample evidence of real risks.

Compounded tirzepatide isn't FDA-approved and has never been subject to the same safety, effectiveness, and strict standards as brand-name Zepbound or Mounjaro. The FDA declared the tirzepatide shortage resolved in December 2024, and as of mid-2025, legal compounding of tirzepatide is largely no longer permitted for 503A or 503B pharmacies.

The safety risks with compounded tirzepatide include dosing errors, differing concentrations, counterfeit products, and little to no premarket quality assurance and review. If you're currently taking compounded tirzepatide or considering it, talk to your healthcare provider.